**Question:** In a case of acute hemarthrosis in hemophilia, treatment with factor VIII along with fresh frozen plasma is given for:

A. Replacing deficient clotting factors
B. Increasing von Willebrand factor levels
C. Inhibiting platelet aggregation
D. Stimulating endothelial cell proliferation

**Correct Answer:** A. Replacing deficient clotting factors

**Core Concept:** Hemophilia is a genetic disorder characterized by deficiency or dysfunction of clotting factors, particularly factor VIII (hemophilia A) and factor IX (hemophilia B). Acute hemarthrosis occurs when there is excessive bleeding into the joints due to impaired clotting.

**Why the Correct Answer is Right:** In hemophilia, factor VIII is absent or functionally impaired, resulting in reduced clotting ability. Factor VIII plays a crucial role in the intrinsic pathway of coagulation, specifically in the activation of factor IX. Treatment with factor VIII aims to replace the deficient clotting factor, allowing the blood clotting process to occur effectively. Fresh frozen plasma (FFP) contains various clotting factors, including factor VIII, which helps to supplement the deficient clotting cascade. By combining factor VIII replacement with FFP, both clotting factors can be supplied simultaneously, leading to better control of bleeding and faster clot formation.

**Why Each Wrong Option is Incorrect:**

**Option B (Increasing von Willebrand factor levels):** Von Willebrand factor (vWF) is essential for platelet adhesion and primary hemostasis, but it is not the primary focus of treatment in hemophilia. While increasing vWF levels might be beneficial in some bleeding disorders, it is not the primary target in hemophilia, where factor VIII deficiency is the critical issue.

**Option C (Inhibiting platelet aggregation):** Hemarthrosis in hemophilia is primarily caused by clotting factor deficiency, not platelet dysfunction. Inhibiting platelet aggregation may indirectly benefit the hemostatic process, but the primary objective is to correct the clotting factor deficiency, not to directly target platelets.

**Option D (Stimulating endothelial cell proliferation):** Endothelial cells play a role in hemostasis, but stimulating their proliferation is not the primary therapeutic goal in hemophilia. The primary focus is on correcting the clotting factor deficiency, not endothelial cell stimulation.

**Why the Correct Answer (Replacing deficient clotting factors):** Both hemophilia A and B are characterized by deficient clotting factors, specifically factor VIII in hemophilia A. Replacing the deficient clotting factor helps to restore the balance in the coagulation cascade and promote effective hemostasis, thereby controlling the excessive bleeding in hemophilia. Fresh frozen plasma (FFP) contains multiple clotting factors, including factor VIII, making it an appropriate choice to supplement the deficient coagulation factors in hemophilia.

**Why Fresh Frozen Plasma (FFP) is chosen over other plasma products:** Fresh frozen plasma (FFP) is derived from the blood of healthy donors and contains various clotting factors, including factor V